You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
Astellas Pharma US President Mark Reisenauer recently joined PhRMA Senior Vice President of State Advocacy Scott LaGanga for a conversation about a range of topics that are important to patients – from the latest in medical science to the ways that biopharmaceutical companies, policymakers and other stakeholders are working to lower out-of-pocket costs.
“The future is incredible,” Mark said. “When you think about what’s possible for patients, in terms of treatment, prevention, and even cures, we’re talking about cures for diseases that we didn’t even have treatments for previously, which is amazing. The prospects are bright, but…we can’t lose sight of the access part of the equation because if patients can’t access these therapies, the technology is all for nothing.”
In his role on the PhRMA Board of Directors, Mark works with his peers and stakeholders across the healthcare system to advocate for state policies that help ensure patients have access to the medicines they need.
“The states that are getting it right are the ones that are looking holistically at the supply chain, but also the ones that are really dealing with the issue that we know patients most care about, which is out-of-pocket costs, what they pay at the pharmacy counter,” Scott stated.
Watch the full discussion below and learn more here.
Get only the email alerts you want.
For media inquiries and reporter requests, please click here to fill out a request form.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.